Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07437105 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Mar 23, 2027 → Jun 26, 2027
Primary endpoint added 2 → 3 primary endpoints
See other at-risk trials from Vertex Pharmaceuticals

Record History

  1. Primary endpoint(s) modified Primary and study completion pushed from Mar 23, 2027 to Jun 26, 2027 · Enrollment increased: 128 → 160 participants · Interventions modified · 4 more Show 7 more changesShow less
    • Primary and study completion pushed from Mar 23, 2027 to Jun 26, 2027
    • Enrollment increased: 128 → 160 participants
    • Interventions modified
    • Trial arms changed: 4 → 6
    • Secondary endpoints: 4 to 8
    • Study description expanded, about 13 words
    • Eligibility criteria expanded, about 5 words
  2. Recruitment opened Study sites: 0 to 1 · Start date changed from estimate of Feb 23, 2026 to Feb 25, 2026 · Eligibility criteria shortened, about 28 words · 1 morev2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 23, 2026 to Feb 25, 2026
    • Eligibility criteria shortened, about 28 words
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272 in combination with deutivacaftor (D-IVA) with or without tezacaftor (TEZ) in healthy subjects.
Trial Details
NCT Number NCT07437105
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Cystic Fibrosis
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov